In the determines all the medicinal specialties of AIFA have been selected band A and of band h who have adhered to the payback extension for 2011, with the exception of those in level A included in the AIFA transparency list as at 30 June 2012.
08 AUG – Published in the Official Gazette n. 183 of 08/07/2012 determines it which establishes the payback procedures for the year 2012. Pursuant to the Law Decree of 29 December 2011 n. 216, the terms of the suspension of the price reduction of the 5% established with Aifa resolution no. 26 of 27 September 2006.
The pay-back shelf mechanism was created to meet the need for greater flexibility in the pharmaceutical market, allowing on the one hand the disbursement of economic resources to the Regions in support of each one's pharmaceutical expenditure, and on the other the opportunity for pharmaceutical companies to make choices on the prices of their drugs, based on their own market intervention strategies. It was envisaged in the 2007 Budget law and allows pharmaceutical companies to ask AIFA to suspend the reduction in the prices of 5%, against the simultaneous cash payment (payback) of the relative value on special current accounts identified by the Regions.
Let's see them procedures of calculation established in the text published in the Official Gazette.
All the class A and class H medicinal products that adhered to the payback extension for 2011 were selected, with the exception of those in class A included in the Aifa transparency list on 30 June 2012. Furthermore, those medicinal products that were marketed during 2011 with at least one month of consumption paid for by the NHS were included, and those authorized after 31 December 2006 which lost in 2011 the requirement of innovation. Relating to this
